HCPLive Network

64th American Academy of Neurology Annual Meeting | AAN 2012

This year's meeting will focus on providing attendees top education, breakthrough science, and practice improvement by offering morning reports, clinical skills pavilions, self-assessment courses, Neuro Flashes, and didactic review and update courses.
AAN 2012 - Day 3
According to a randomized, controlled clinical trial reported at the Emerging Science session, pregabalin was found effective in relieving chronic neuropathic pain and pain-related sleep disturbances associated with spinal cord injury.
Although the intra-cerebral hemorrhage (ICH) score at hospital admission is typically used to estimate the potential prognosis in stroke patients, a new study suggests that the 24-hour ICH score is a more accurate assessment.
In the first long-term active-comparator trial of efficacy and augmentation in restless leg syndrome (RLS), outcomes with pregabalin were better than those observed with pramipexole.
AAN 2012 - Day 2
The 2012 Annual Meeting of the American Academy of Neurology presented a phase 3 randomized, double-blind clinical trial which found that levodopa-carbidopa intestinal gel was more effective than standard oral levodopa-carbidopa.
Mark F. Mehler, MD, discussed how brain and behavior are becoming better understood through the emerging discipline of epigenetics.
Results from the FREEDOMS II trial found oral fingolimod administered at a daily dose of 0.5 mg to reduce relapse rates by almost 50% in patients with relapsing-remitting multiple sclerosis (RRMS).
AAN 2012 - Day 1
A new study presented at the 2012 Annual Meeting of the American Academy of Neurology suggests that the drug florbetaben can be used as a biomarker with positron emission tomography (PET) imaging to diagnose AD by detecting amyloid plaques in the brains of living people suspected of having AD.
Updated guidelines for prevention of chronic migraine headache were unveiled during the 2012 Annual Meeting of the American Academy of Neurology.
An investigational oral drug for multiple sclerosis (MS), called ONO-4641, reduced the number of lesions detected on magnetic resonance imaging (MRI) scans
Pre Meeting
At this year's meeting, the AAN will be hosting various scientific and plenary session focusing on the hot topics in neurology.
This year's American Academy of Neurology Annual Meeting is being hosted in New Orleans, LA from April 21-27, which is known for its ecletic cuisine. Here are some ideas of restaurants to check out.
At this year's AAN Annual Meeting, attendees will find exciting ways to explore New Orleans and can take advantage of the various downtime activities hosted by the AAN such as morning yoga or tennis.
In this interview, Michael Zigmond, PhD, previews his lecture to be given at this year's AAN Annual Meeting. Zigmond explains how he became involved with studying Parkinson's disease (PD), research with exercise and PD, and what his intentions are with helping to fight this disease.
Dr. Sacco highlights some of the key takeaway points that he will speaking about during the Robert Wartenberg Lecture at this year's AAN Annual Meeting. He also discusses his involvement in the Northern Manhattan Study, which evaluates stroke in African and Hispanic Americans.
$AD300x250BB$